Digital health company Akili Interactive has agreed a deal that could see its gamified therapy for attention-deficit hyperactivity disorder (ADHD) hosted on the creative gaming platform Rob
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.
